@medchemexpress.bsky.social
MedChemExpress (MCE) | US Headquartered 🌎 Global Warehousing Inhibitors ＆ Agonists | Proteins | Drug Screening Platform
@medchemexpress.bsky.socialThe FDA has approved #Hovilpri (#pritelivir) for adults with weakened immune systems who have mucocutaneous lesions caused by HSV infection that have not responded to other treatments.
🧪Pritelivir for research use from MedChemExpress: https://www.medchemexpress.com/BAY-57-1293.html
@medchemexpress.bsky.social💊FDA Approvals | Notable Recent Oncology Drugs
🔹#Atezolizumab + chemo— Stage III dMMR colon cancer
🔹#Tucatinib combo— HER2+ breast cancer
🔹#Pirtobrutinib— BTK inhibitor for CLL/SLL
🔹#Belzutifan + #Lenvatinib— advanced ccRCC
🔎Discover bioactive molecules for your research: https://ow.ly/2s0R50ZWcts
@medchemexpress.bsky.social🦟West Nile virus (#WNV) is a mosquito-borne virus. 16 European countries had reported 1,765 locally acquired human cases, according to ECDC. Most infections cause no symptoms, but severe neurological complications can occur. Prevent bites with repellent, long sleeves, and by removing standing water.
@medchemexpress.bsky.socialThe FDA has approved Pfizer’s #TUKYSA (#tucatinib) + #trastuzumab + #pertuzumab for adults with unresectable locally advanced or metastatic HER2-positive breast cancer following induction treatment.
🧪Tucatinib for research use from MedChemExpress: https://www.medchemexpress.com/Irbinitinib.html
@medchemexpress.bsky.social🏆 Nobel Prize 2026: From Chirality to Drug Discovery Left or right? For life, the choice matters. Henri B. Kagan and Kenso Soai showed how small imbalances can amplify chirality through nonlinear effects and asymmetric autocatalysis. 💊 Different enantiomers can have different biological activities.
@medchemexpress.bsky.socialThe FDA has approved #Emcitate (#tiratricol) for the treatment of peripheral thyrotoxicosis in patients with #MCT8 deficiency.
📊Emcitate reduced elevated thyroid hormone levels, improved cardiovascular and metabolic measures
Explore Tiratricol for research use from MCE: https://ow.ly/aQEr50ZVIJZ
@medchemexpress.bsky.social🏆 #NobelPrize 2026 | #Optogenetics
Karl Deisseroth, Peter Hegemann & Georg Nagel have won the Nobel Prize in Physiology or Medicine. 🧠
💡 Their work enables researchers to switch individual nerve cells on or off with light—transforming #neuroscience and how we understand the brain.
@medchemexpress.bsky.social🏆#NobelPrize 2026 Countdown | 06 Integrins & cell adhesion
How do immune cells know where to go?
Timothy A. Springer helped reveal how integrins control immune-cell adhesion and migration, paving the way for therapies like #vedolizumab.
🔬Countdown complete. Nobel Prize announcement: Oct. 5.
@medchemexpress.bsky.social🏆#NobelPrize 2026 Countdown | 05 cGAS–STING & innate immunity
How does the immune system detect dangerous DNA?
Zhijian “James” Chen & Glen Barber helped reveal how cGAS senses cytoplasmic DNA and activates STING, triggering innate immunity.
From DNA sensing to cancer immunotherapy.
@medchemexpress.bsky.social🏆 #NobelPrize 2026 Countdown | 04 CAR-T & cancer therapy
Can a patient’s own immune cells become a living cancer treatment?
Zelig Eshhar, Carl June & Michel Sadelain helped turn CAR-T from concept into clinical therapy—engineering T cells to recognize and attack cancer cells.
@medchemexpress.bsky.social🏆#NobelPrize2026 Countdown | 03🩸Bispecific antibodies&hemophilia
In 2026, Hiroshi Hattori, Tomoyuki Igawa&Takehisa Kitazawa received the Lasker Clinical Medical Research Award for developing emicizumab. By binding factor IXa&X, emicizumab mimics factor VIII and helps prevent bleeding in hemophiliaA.
@medchemexpress.bsky.social🏆#NobelPrize 2026 Countdown | 02 😴Orexin & sleep
In 2026, Yanagisawa & Emmanuel Mignot received the Lasker Basic Medical Research Award for discovering orexin and its link to narcolepsy. From receptor biology to disease research, their work revealed how orexin helps regulate sleep and wakefulness.
@medchemexpress.bsky.social🏆#NobelPrize 2026 Countdown | 01
GLP-1 has reshaped metabolic medicine, from diabetes and obesity to cardiovascular health.
In 2026, Daniel J. Drucker, Jens Juul Holst&Svetlana Mojsov were named Citation Laureates for their work on GLP-1. From discovery→drug development→clinical impact
👀What’s next?
@medchemexpress.bsky.social🧬Can one kinase be targeted at two sites? A study introduces bitopic inhibition using BCR::ABL1 as a model. PonatiLink-2 links ponatinib and asciminib to target the ATP and allosteric sites, improving activity against resistant mutants and kinase selectivity. The strategy was also extended to EGFR.
@medchemexpress.bsky.socialSeptember: #MuscularDystrophy Awareness Month
🔹DMD | PMO exon skipping; PPMOs & AOCs aim to improve muscle delivery
🔹DM1 | ASOs & AOCs target DMPK RNA
🔹OPMD | Gene therapy approaches are under exploration
🔹LGMD | Gene therapy & oligonucleotide approaches are being investigated for selected subtypes
@medchemexpress.bsky.social🩺World Heart Day | Sept. 29: “Don’t Miss a Beat”
Cardiovascular disease (CVD) can develop silently. Everyone needs to raise awareness.
Ongoing research is uncovering new therapeutic opportunities across lipid metabolism, thrombosis, and heart failure. https://ow.ly/aX3Y50ZSvfK
@medchemexpress.bsky.socialCell death is not a single process. Beyond well-known apoptosis, researchers have uncovered diverse regulated cell-death pathways, including:
🔹Apoptosis
🔹Necroptosis
🔹Pyroptosis
🔹Ferroptosis
🔹Autophagy-dependent cell death and other emerging mechanisms
📰Read more: https://ow.ly/XrWZ50ZQpky
@medchemexpress.bsky.social🧬How is the drug target landscape evolving? A review found 686 biomolecular targets behind 1,702 approved drugs as of June 2025. 🔹 Peptide targets ↑ 7.2-fold 🔹 136 kinase inhibitors target 67 kinases 🔹 New modalities are expanding the druggable space.
@medchemexpress.bsky.social🧬What if we could degrade ALK instead of just inhibiting it? Nature highlights TRI-611, a brain-penetrant molecular glue degrader targeting ALK fusion proteins, including TKI-resistant variants. Could targeted protein degradation offer a new strategy for ALK+ NSCLC?
@medchemexpress.bsky.social#MYH9 Emerges as a Key Executor of #Cuproptosis
A new study in Cell identifies MYH9 as a key executioner of cuproptosis, a copper-dependent form of cell death.
🧫Copper binds MYH9 → MYH9 polymerization → Cytoskeleton disruption → Cell death
